AKRO

Efruxifermin (AKR-001)

Non-alcoholic Steatohepatitis (NASH)

Phase 2a readout

Exp Date

H1 2020

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE:  Efruxifermin for Non-alcoholic Steatohepatitis (NASH) Phase 2a readout

  • Clinical Trial (NCT03976401): A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2a readout

  • Phase 2b/3 to be initiated


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H1 2021 

  • H1 2021


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION

  • Efruxifermin (EFX), formerly known as AKR-001, is Akero’s lead product candidate for NASH, currently being evaluated in the ongoing Phase 2a BALANCED study. EFX is designed to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and improve lipoproteins. This holistic approach offers the potential to address the complex, multi-system disease state of NASH, including improvements in lipoprotein risk factors linked to cardiovascular disease – the leading cause of death in NASH patients. Engineered to mimic the biological activity profile of native FGF21, EFX offers convenient once-weekly dosing and has been generally well-tolerated in clinical trials to date.

Updated by MV

AKR001, NASH, nonalcoholic steatohepatitis, AKRO, Akeiro, liver disease

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

ICPT - Type A Meeting held wit...

#ICPT reported their Type A Meeting the U.S. Food and Drug Administration regarding Ocaliva for Adult nonalcoholic steatohepatitis (NASH). “We were pleased to reengage with FDA at our recent Type A ...

ICPT CRL for Ocaliva
...

Intercept Pharmaceuticals, Inc. received a Complete Response Letter from the U.S. FDA for the NDA for Ocaliva which is used for Adult nonalcoholic steatohepatitis (NASH). The FDA stated that the CRL w...

Do prior negative Seladalpar r...

We started to dig into this question. See our in-process diligence HERE, and share your thoughts. We'd love to hear from you. #GNFT #Elafibranor #NASH #Readout #Seladalpar ...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon